House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Nephrology · Cardiology

Cardiovascular disease and chronic kidney disease

ESC · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

Focused recommendations from the official 2026 ESC/ERA cardiovascular–kidney guideline slides. The approach combines kidney staging with cardiovascular prevention and disease-specific treatment, preserving kidney-function, albuminuria and dialysis boundaries. Recommendation classes are retained for selected decisions. This is not a complete prescribing or advanced-kidney-disease protocol.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Stage kidney disease and identify risk

  • Use a validated creatinine-based eGFR and morning spot urinary albumin:creatinine ratio (uACR) to classify CKD. Confirm chronicity with two eGFR/uACR measurements over at least 3 months. These are Class I recommendations; chronicity confirmation has level C evidence. [1]
  • Screen people with cardiovascular disease using eGFR and albuminuria. Repeat unexpectedly low eGFR or new albuminuria within days to weeks so acute kidney injury is recognised promptly rather than assumed chronic. Both are Class I, level C. [1]
  • Use a validated Kidney Failure Risk Equation in CKD G3–G5 to estimate kidney-replacement risk and support timely nephrology referral (Class I, A). At each CKD encounter, assess for hypertension, atherosclerotic disease, heart failure, arrhythmia and valve disease (Class I, C). [1]
  • For CKD medicines with renal elimination and narrow therapeutic windows or kidney-related adverse effects, monitor eGFR, relevant electrolytes, indicated ECG QT intervals and available drug levels. Assess benefit versus harm before potentially nephrotoxic treatment (Class I, C). [1]

Prevent cardiovascular complications

  • Recommend smoking cessation and an individualised vegetable-rich diet with sodium below 2 g/day, equivalent to salt below 5 g/day. Recommend physical activity, such as at least 150 minutes of moderate activity weekly where possible (Class I recommendations). [1]
  • For CKD with eGFR at least 30 mL/min/1.73 m², intensify lifestyle and drug treatment when confirmed standardised office BP is at least 130/80 mmHg and target systolic 120–129 if tolerated (Class I, A). Below eGFR 30, individualise the BP target (Class I, C). [1]
  • For CKD with eGFR below 60 mL/min/1.73 m² without kidney-replacement therapy, recommend an intensive statin-based regimen shown safe in CKD, regardless of lipid level (Class I, A). Dialysis recommendations are weaker: continuing treatment at dialysis initiation may be considered (Class IIb, C). [1]
  • Do not routinely use antiplatelet therapy for CKD with eGFR below 60 mL/min/1.73 m² without symptomatic atherosclerotic cardiovascular disease, because bleeding may outweigh benefit (Class III, B1). [1]

Retain kidney and albuminuria treatment boundaries

  • Recommend an SGLT2 inhibitor for CKD with type 2 diabetes and eGFR at least 20 mL/min/1.73 m² regardless of glycaemic control (Class I, A). Without diabetes, the Class I/A recommendation requires that eGFR threshold plus uACR at least 20 mg/mmol (200 mg/g). [1]
  • Without diabetes, consider an SGLT2 inhibitor for eGFR 20–44 mL/min/1.73 m² and uACR below 20 mg/mmol to slow progression (Class IIa, B1). Do not combine an ACE inhibitor and ARB in CKD because of acute kidney injury and severe hyperkalaemia (Class III, A). [1]
  • For CKD with type 2 diabetes, the semaglutide recommendation applies to eGFR 25–49 with uACR at least 10 mg/mmol, or eGFR 50–74 with uACR at least 30 mg/mmol, using subcutaneous 1.0 mg weekly after titration, regardless of glycaemic control (Class I, A; eGFR in mL/min/1.73 m²). [1]

Treat heart failure within renal-function limits

  • In heart failure with CKD, recommend loop diuretics for fluid overload and SGLT2 inhibition at eGFR at least 20 mL/min/1.73 m² regardless of ejection fraction (Class I, A). For HFrEF, steroidal MRA treatment has a Class I/A recommendation at eGFR at least 30. [1]
  • For HFrEF and CKD with eGFR at least 30 mL/min/1.73 m², recommend ACE inhibitor or ARNI, or ARB if these are intolerable, and a beta-blocker (Class I, A). These recommendations do not establish the same strength below that kidney-function threshold. [1]
  • In congested decompensated heart failure with CKD not on kidney-replacement therapy, continue decongestion despite a creatinine increase up to 50% when diuretic response is good (Class I, C). This recommendation requires ongoing congestion and a good response. [1]
  • For heart failure with CKD, consider continuing an existing SGLT2 inhibitor if eGFR falls below 20, or an existing ARNI below 30 mL/min/1.73 m², to avoid worsening heart failure (Class IIa, C). These are continuation decisions, not new-start thresholds. [1]

Distinguish stable disease, acute events and atrial fibrillation

  • In chronic coronary syndrome with CKD, recommend an initial conservative strategy with optimal medical treatment (Class I, B1), while individualising revascularisation through multidisciplinary assessment of anatomy, risks, benefits and preferences (Class I, C). [1]
  • CKD should not delay immediate or early invasive treatment for STEMI or high/very-high-risk non-ST-elevation acute coronary syndrome (Class I, C). This acute-event recommendation is distinct from the stable-coronary pathway. [1]
  • For atrial fibrillation with eGFR below 30 mL/min/1.73 m², existing ischaemic-stroke and bleeding scores are not recommended, even if they include kidney measures, because prediction is poor (Class III; levels B and C respectively). [1]
  • For atrial fibrillation and CKD, prefer a DOAC over a vitamin-K antagonist at eGFR at least 30 mL/min/1.73 m² (Class I, A); consider an oral factor-Xa inhibitor at 15–29 (Class IIa, B1). Below 15, including kidney-replacement therapy, consider individualised benefit–risk decisions (Class IIa, C). [1]

Plan procedures and multidisciplinary care

  • For coronary or vascular procedures in nondialysis CKD with eGFR below 30 mL/min/1.73 m², use low- or iso-osmolar iodinated contrast with contrast-sparing techniques (Class I, A). Do not use prophylactic haemodialysis to prevent contrast-associated kidney injury (Class III, B2). [1]
  • For nondialysis CKD with eGFR below 30 mL/min/1.73 m² undergoing iodinated-contrast procedures, intravenous periprocedural hydration may be considered (Class IIb, C). Consider risk assessment incorporating eGFR, patient factors and the planned procedure (Class IIa, C). [1]
  • Routine MRA use is not recommended on dialysis because severe hyperkalaemia risk is not offset by clear cardiovascular-death or heart-failure-admission benefit (Class III, A). Consider nephrology involvement in cardiovascular teams for eGFR below 30 mL/min/1.73 m² or kidney-replacement therapy (Class IIa, C). [1]

Limitations and use

  • This focused selection does not reproduce every valve, peripheral-vascular, stroke, transplant, anticoagulant-dose or advanced-heart-failure pathway. Drug initiation requires the full eligibility, contraindication and monitoring assessment; numerical thresholds here are not standalone prescriptions.
  • The source is the official ESC educational recommendation set. Complete drug-specific conditions and full guideline footnotes, including those for finerenone, must be consulted before applying recommendations omitted from this summary.
  • European risk models, medicine availability and treatment systems require local assessment for Indian patients; this summary does not establish population-specific calibration or local regulatory approval.
  • This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Cardiovascular disease and chronic kidney disease — focused recommendation source

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
ESC
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Stage kidney disease and identify risk
  • Prevent cardiovascular complications
  • Retain kidney and albuminuria treatment boundaries
  • Treat heart failure within renal-function limits
  • Distinguish stable disease, acute events and atrial fibrillation
  • Plan procedures and multidisciplinary care
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House